Norbert Pardi Editor

Gabor Tamas Szabo is associate director in the Protein Replacement Therapies working group headed by Prof. Katalin Kariko at BioNTech SE, Germany. Dr. Szabo was member of the LightSpeed Project at BioNTech, in which program the first ever authorized mRNA vaccine was developed.

Norbert Pardi is an assistant professor at the University of Pennsylvania, USA. His research interest is the development of mRNA-based therapeutics with focus on vaccines. In his lab, mRNA-LNP vaccines are designed and tested against various pathogens. Dr. Pardi is a member of the planning committee of the annual International mRNA Health Conference.